Clinical Trials Directory

Trials / Completed

CompletedNCT02915900

Optimising FSH Dosage During in Vitro Fertilization Fertilization (IVF)

Method for Determining Optimal FSH Dosage During in Vitro Fertilization (IVF)

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
196 (actual)
Sponsor
Oslo University Hospital · Academic / Other
Sex
Female
Age
18 Years – 38 Years
Healthy volunteers
Not accepted

Summary

During in vitro fertilisation (IVF) treatment, women receive hormone stimulation with gonadotropins to induce growth of several ovarian follicles. Selecting the optimal dosage of gonadotropin is important to avoid maturation of too few or too many follicles, which may impair the chances of treatment success, lead to treatment cancellation, or serious side effects. Motivated by the lack of standardised procedures to estimate the optimal dosage of gonadotropins, a patient-specific test has been developed to predict the optimal hormone dosage. By measuring internalisation of gonadotropin by the patient's monocytes isolated form the peripheral blood ex vivo, the Gonadotropin Removal Test determines whether a patient needs increased or reduced hormon doses. In this clinical study the investigators compare deviation from optimal outcome at oocyte pick-up day in two patient groups. Optimal outcome of stimulation is defined as 10 oocytes collected in the group of patients matching the inclusion criteria of the study. The control group receives starting hormone dosage assigned by the clinician according to standard clinical procedures. The intervention group receives starting hormone dosage adjusted according to the results of the Gonadotropin Removal Test.

Conditions

Interventions

TypeNameDescription
OTHERGonadotropin removal testPatient receives hormone dosage adjusted according to the results of the Gonadotropin removal test.
OTHERRoutine IVF methodPatient receives hormone dosage according to the standard dosage regimen, without revealing the results of the Gonadotropin removal test to the clinician.

Timeline

Start date
2014-10-01
Primary completion
2016-12-01
Completion
2017-07-01
First posted
2016-09-27
Last updated
2017-09-19

Locations

1 site across 1 country: Norway

Source: ClinicalTrials.gov record NCT02915900. Inclusion in this directory is not an endorsement.